Investing in the most popular players in the space isn't the only valid approach.The ecosystem of companies competing to develop therapies for weight loss is growing every day, and there's more than one competitor that's investment-ready. While many investors look to small and risky biotechs to get exposure, there are larger and safer options, too.Today, we'll discuss two such options. Neither is a leader in the weight loss space just yet, but with promising irons in the fire, they're positioned to have a s ...

Amgen (AMGN) closed at $319.66 in the latest trading session, marking a +0.69% move from the prior day. The stock lagged the S&P 500's daily gain of 0.9%. Elsewhere, the Dow gained 0.81%, while the tech-heavy Nasdaq added 1.22%.The the stock of world's largest biotech drugmaker has fallen by 2.12% in the past month, leading the Medical sector's loss of 4.05% and undershooting the S&P 500's gain of 3.15%.The investment community will be paying close attention to the earnings performance of Amgen in its upcom ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation ...

Shares of Amgen (AMGN) fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the autoimmune disease space. While the studies did meet their respective primary endpoints, Wall Street termed the results ‘lackluster’ and ‘underwhelming’.At a conference call on Tuesday, Amgen posted top-line data from two late-stage studies — HORIZON and MINT. The HORIZON study evaluated an investigational anti-OX40 therapy rocatinlimab in atopic dermatitis (AD or eczema) indication. In the ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.Shares of Amgen (NASDAQ: AMGN ) are down this week despite two positive ...

In an investor update on Tuesday, Amgen Inc AMGN released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab).HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) in 726 patients.Amgen reported that rocatinlimab outperformed a placebo regarding the severity and extent of the disease.Amgen stock is trading lower as the data seemed to be below expectations.Goldman Sachs notes that although the Phase 3 efficacy data for rocatinlimab is less compelling compared to Dupixent ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) is a leading biotechnology company based in Tarrytown, New York. REGN develops therapies for eye diseases, cancer, allergic conditions, and infectious diseases. Its portfolio contains commercial Eylea, Dupixent, and Libtayo that address critical medical needs andMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from ...

Shares of Regeneron Pharmaceuticals, Inc. (REGN) were down 4.63% after an unfavorable ruling in its lawsuit against Amgen (AMGN) in the United States District Court for the Northern District of West Virginia.The lawsuit was related to a biosimilar of its lead drug Eylea (aflibercept 2 mg).Regeneron’s shares have rallied 24.3% year to date against the industry’s decline of 1.5%.Image Source: Zacks Investment ResearchREGN’s Lawsuit Against AMGNEylea, REGN’s lead drug, is approved for various retinal condition ...

Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.It's hard to overstate just how successful weight-management treatments have been over the past couple of years. Sales of semaglutide, the drug that Novo Nordisk (NVO -2.99%) markets as Ozempic and Rybelsus for diabetes, and as Wegovy for weight management, have soared to an annualized $27.9 billion.Semaglutide first earned approval from the Food and Drug Administration (FDA) back in 2017. A much younger treatme ...